Comparative Efficacy of Olmesartan and Perindopril on the Effect on Central Blood Pressure and Elastic Properties of the Arteries in Patients with Mild to Moderate Hypertension

Yu.N. Sirenko, O.L. Rekovets, S.N. Kushnir


Introduction. Central aortic pressure is a precise criterion of target organ damage and cardiovascular mortality compared with brachial artery pressure.
Objective. To compare the efficacy of olmesartan and perindopril in reduction of central aortic pressure and improvement of the elastic properties of arteries in patients with mild to moderate arterial hypertension (AH).
Materials and Methods. We carried out an observation including 40 patients with mild to moderate hypertension (20 men, 20 women). All patients were divided into 2 groups — treatment with perindopril 4–8 mg/daily (n = 20) and olmesartan 20–40 mg/daily (n = 20). When the target blood pressure (BP) levels were no achieved torasemide 5 mg/daily was added. The procedure of examination at baseline and after 6 months included office systolic (SBP) and diastolic (DBP) blood pressure measurements, ambulatory blood pressure monitoring (ABPM), central blood pressure measurement, estimation of pulse wave velocity (PWV) and assess the level of blood lipids.
Results. After 6 months of therapy there was a significant reduction in office systolic and diastolic blood pressure levels in both groups by 30.05/16.25 mmHg in olmesartan group and 30.6/16.10 mmHg in perindopril group. Such significant reduction of office BP may be explained by that after 1 month of treatment, in case of target BP levels were not achieved, torasemide was added.
The level of central SBP was significantly decreased in both groups, about 20.13 ± 5.89 mmHg in the olmesartan group and 16.15 ± 4.59 mmHg in perindopril group. The difference in the central SBP levels was 4 mmHg. In olmesartan group АIх decreased by 8.13 % and by 2.6 % in perindopril group (p < 0.05). For both groups it was shown an improvement of elastic properties of arteries due to PWV reduction in elastic arteries. In olmesartan group PWV in elastic arteries decreased by 2.43 m/s and in perindopril group — by 1 m/s (p > 0.05 between groups, probably due to the small number of observations). In torasemide subgroupы сSBP decrease did not significantly differ, it was 12.43 mmHg for combination olmesartan + torasemide and 13.67 mmHg for combination perindopril + torasemide subgroups. In olmesartan + torasemide subgroup АIх decreased by 14.4 %, and in perindopril + torasemide subgroup it did not change (p < 0.05 between groups). In olmesartan monotherapy, PWV in elastic arteries decreased by 2.72 m/s compared to 0.88 m/s in perindopril monotherapy (p < 0.05 between subgroups).
Conclusion. Central aortic pressure in both groups decreased significantly equally. With the same reduction of office BP and BP in ABPM, in olmesartan group АIх decreased significantly both in monotherapy and in combination with torasemide, compared with perindopril group. PWV decreased in both groups, but in olmesartan monotherapy this decrease was significantly greater compared to perindopril monotherapy.


hypertension; olmesartan; perindopril; central aortic pressure; pulse wave velocity


Клінічні рекомендації з артеріальної гіпертензії Європейського товариства з гіпертензій (ESH) та Європейського товариства кардіологів (ESC) 2013 року / Пер. Ю.М. Сіренка // Артеріальна гіпертензія. — 2013. — № 4 .— С. 62-157.

Маликов М. Жесткость сосудов как универсальный фактор риска у пациентов с артериальной гипертензией // Здоровье Украины. — 2012. — № 25. — С. 52-53.

Радченко А.Д., Михеева К.В., Сиренко Ю.Н. и др. Клиническое исследование ЭЛИЗА. Результаты 6-месячного наблюдения. — Донецк: Издатель Заславский А.Ю., 2011. — 64 с.

Cиренко Ю.Н., Рековец О.Л., Багрий А.Э., Визир В.А. Антигипертензивная эффективность фиксированной комбинации валсартана и амлодипина (препарата Эксфорж) у пациентов с артериальной гипертензией (результаты многоцентрового исследования) // Артериальная гипертензия. — 2012. — № 1. — С. 46-56.

Achhammer I., Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide // Drugs — 1991 — Vol. 41, Suppl. 3. — P. 80-91.

Agabiti-Rosei E, Rizzoni D. Regression of small resistance artery structural alterations in hypertension by appropriate antihypertensive treatment // Curr. Hypertens. Rep. — 2010. — Vol. 12. — P. 80-85.

Barrios V., Boccanelli A., Ewald S., Girerd X., Heagerty A., Krzesinski J.M., Lins R., Rodicio J., Stefenelli T., Woittiez A., Böhm M. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study // Clin. Drug Investig. — 2007 — Vol. 27 — P. 545-558.

Bavry A.A., Anderson R.D., Gong Y. et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy // Hypertension. — 2010. — Vol. 55. — P. 48-53.

Bergmann K., Laeis P., Püchler K., Sudhop T., Schwocho L.R., Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of lmesartan medoxomil // J. Hypertens. Suppl. — 2001. — Vol. 19 — P. S33-40.

Boutouyrie P., Achouba A., Trunet P., Laurent S.; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study // Hypertension. — 2010. — Vol. 55. — P. 1314-1322.

Brunner H.R. Olmesartan medoxomil: current status of its use in monotherapy // Vasc. Health Risk Manag. — 2006. — Vol. 2. — P. 327-340.

Chuang Y.C., Wu M.S., Su Y.K., Fang K.M. Effects of olmesartan on arterial stiffness in rats with chronic renal failure // Cardiovasc. Diabetol. — 2012. — Vol. 13. — P. 11-66.

Gupta A.K., Nasothimiou E.G., Chang C.L., Sever P.S., Dahlöf B., Poulter N.R. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk // J. Hypertens. — 2011 — Vol. 29. — P. 2004-2013.

Holtkamp F.A., de Zeeuw D., de Graeff P.A., Laverman G.D., Berl T., Remuzzi G., Packham D., Lewis J.B., Parving H.H., Lambers Heerspink H.J. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials // Eur. Heart J. — 2011. — Vol. 32. — P. 1493-1499.

Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) // Arch. Intern. Med. — 1997. — Vol. 157. — P. 2413-2446.

Kario K., Saito I., Kushiro T., Teramukai S., Mori Y., Hiramatsu K., Kobayashi F., Shimada K. Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study // J. Clin. Hypertens (Greenwich). — 2013 — Vol. 15 — P. 555-561.

Kruck F. Acute and long-term effects of loop diuretics in heart failure // Drugs. — 1991. — Vol. 41, Suppl. 3. — P. 60-68.

Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. — 2009. — Vol. 19. — P. 338:b1665.

London G.M. Arterial calcification: cardiovascular function and clinical outcome // Nefrologia. — 2011. — Vol. 31. — P. 644-647.

Mackenzie I.S., McEniery C.M., Dhakam Z. et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension // Hypertension. — 2009. — Vol. 54. — P. 409-413.

Manisty C.H., Hughes A.D. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index // Br. J. Clin. Pharmacol. — 2013. — Vol. 75. — P. 79-92.

Matsui Y., O’Rourke M.F., Ishikawa J., Shimada K., Kario K. Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study // Am. J. Hypertens. — 2012 — Vol. 25 — P. 862-868.

Matsui Y., Eguchi K., Michael F. O’Rourke et al. Differential Effects Between a Calcium Channel Blocker and Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients // Hypertension. — 2009. — Vol. 54. — P. 716-723.

Mazzolai L., Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists // Drug Saf. — 1999. — Vol. 21. — P. 23-33.

Ong K.T., Delerme S., Pannier B. et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients // J. Hypertens. — 2011. — Vol. 29. — P. 1034-1042.

Pannier B., Guérin A.P., Marchais S.J., Safar M.E., London G.M. Central artery pulse pressure in end-stage renal disease: the roles of aortic diameter, aortic stiffness and wave reflection // Blood Purif. — 2011 — Vol. 31 — P. 107-112.

Püchler K., Laeis P., Stumpe K.O. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist // J. Hypertens. Suppl. — 2001. — Vol. 19. — P. S41-48.

Reyes A., Chiesa P., Santucci M. et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as. once daily antihyper-tensive monopharmacotherapy in elderly patients; randomized and double-blind study // Progress in Pharmacology and Clinical Pharmacology. — Gustav-Fischer-Verlag: Stuttgart, 1990. — Vol. 8 .— P. 183-209.

Roth E.M., Oparil S., Melino M., Lee J., Fernandez V., Heyrman R. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis // J. Clin. Hypertens (Greenwich). — 2013. — Vol. 15. — P. 584-592.

Ruilope L.M., Schaefer A. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study // Contemp. Clin. Trials. — 2011. — Vol. 32. — P. 710-716.

Safar M.E. Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension // Int. J. Nephrol. Renovasc. Dis. — 2010. — Vol. 3. — P. 167-173.

Sharman J.E., Marwick T.H., Abhayaratna W.P. et al. Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing managEment of hypertension: the BP GUIDE study // Am. Heart J. — 2012. — Vol. 163. — P. 761-767.

Stumpe K.O., Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs // J. Hum. Hypertens. — 2002. — Vol. 16, Suppl. 2. — S24-28.

Takami T., Saito Y. Azelnidipine plus olmesartan versus amlodipine plus olmesartan in arterial stiffness and cardiac function in hypertensive patients: a randomized trial // Drug Des. Devel. Ther. — 2013. — Vol. 22. — P. 175-183.

Takami T., Saito Y. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study // Vasc. Health Risk Manag. — 2011. — Vol. 7. — P. 383-390.

Tomlinson L.A., Selvarajah V., Wilkinson I.B. Rate-limiting step: can different effects of antihypertensives on central blood pressure be translated into outcomes? // Hypertension. — 2011. — Vol. 57. — P. 1047-1048.

Wang K.L., Cheng H.M., Chuang S.Y. et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? // J. Hypertens. — 2009. — Vol. 27. — P. 461-467.

Wang L., Zhao J.W., Liu S. et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis // Am. J. Cardiovasc. Drugs. — 2012. — Vol. 1. — P. 335-344.

Williams B., Lacy P.S., Thom S.M. et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113. — P. 1213-1225.



  • There are currently no refbacks.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг